A new clinical trial has revealed encouraging results for a muscle-targeting therapy aimed at improving motor function in children and adolescents with spinal muscular atrophy, according to a study published in The Lancet Neurology. Spinal muscular atrophy (SMA) is a rare genetic disorder that affects motor neurons – nerve cells in the spinal cord responsible for controlling voluntary…
New Delhi: The GST rate cuts announced last week will make medicines used for the treatment of critical conditions like multiple myeloma, lung cancer, blood cancer, lymphoma, Gaucher disease, Pompe disease and haemophilia significantly cheaper and help more patients to avail of treatment, health experts said. A pack of leukaemia drug asciminib 60 (40 mg…
Spinal muscular atrophy (SMA) is a rare genetic condition that causes progressive muscle weakness, which, when untreated, prevents infants with the most severe form from gaining motor development – never gaining the ability to sit – and typically leads to death before 2 years of age. The oral drug risdiplam benefits symptomatic patients with improved…